☆ 4.5 Review

Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+/Her2-breast cancer

BREAST CANCER RESEARCH AND TREATMENT (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2L early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2L trial

O. Gluz et al.

Summary: In high-risk HR+/HER2- early breast cancer, nanoparticle albumin-bound (nab)-paclitaxel showed promising efficacy versus solvent-based (sb)-paclitaxel in neoadjuvant trials. However, optimal patient and therapy selection remains a topic of ongoing research.

ANNALS OF ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

Christina Yau et al.

Summary: This study analyzed data from multiple independent cohorts to evaluate the relationship between residual cancer burden (RCB) and long-term prognosis in different subtypes of breast cancer. The results showed that higher RCB score was significantly associated with worse event-free survival in all breast cancer subtypes. The study suggests considering the evaluation of RCB as part of standard pathology reporting.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67

Judy C. Boughey et al.

Summary: In ER+/HER2- breast cancer, nodal downstaging with NAC is associated with age (< 50 years) and Ki67 (>= 20%). Age and Ki67 should be considered for NAC decision-making and can identify patients with high rates of nodal downstaging (36%) who would benefit from NAC to enable axillary preservation.

ANNALS OF SURGICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Breast Cancer Statistics, 2022

Angela N. Giaquinto et al.

Summary: This article provides an update on female breast cancer statistics in the United States, including data on incidence, mortality, survival, and mammography screening. It shows that breast cancer incidence rates have increased over the past few decades, driven by localized-stage and hormone receptor-positive disease. However, breast cancer mortality rates have been steadily declining since 1989, although at a slower pace in recent years. Despite lower incidence rates, there remains a racial disparity in breast cancer mortality, with higher rates among Black women compared to White women.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

添加到收藏夹

Article Oncology

Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature

Pat W. Whitworth et al.

Summary: This study investigates the impact of molecular subtyping based on an 80-gene signature on the neoadjuvant treatment response and 5-year outcome of breast cancer patients. The results show that reclassifying a subset of estrogen receptor-positive, human epidermal growth factor receptor 2-negative tumors as basal-type is associated with similar treatment response and better prognosis compared to triple-negative breast cancer. These findings highlight the importance of identifying this subtype of patients for improved treatment planning and long-term survival.

JCO PRECISION ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

Kevin Kalinsky et al.

Summary: The study showed that among premenopausal women with hormone-receptor-positive, HER2-negative breast cancer and one to three positive lymph nodes with a recurrence score of 25 or lower, the addition of chemotherapy to endocrine therapy led to longer invasive disease-free survival and distant relapse-free survival compared to endocrine therapy alone. However, postmenopausal women with similar characteristics did not benefit from adjuvant chemotherapy in terms of invasive disease-free survival.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

Larissa A. Korde et al.

Summary: The guideline recommendations for neoadjuvant therapy for breast cancer suggest that patients should be managed by multidisciplinary teams and that appropriate candidates include those with inflammatory breast cancer or residual disease that may prompt a change in therapy.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

Martine Piccart et al.

Summary: The MINDACT trial demonstrated that patients with breast cancer of high clinical and low genomic risk who did not receive chemotherapy had excellent 5-year distant metastasis-free survival. The long-term follow-up results, including exploratory analysis by age, further support the use of genomic testing in identifying patients who can forgo chemotherapy. Chemotherapy showed different effects on distant metastasis-free survival based on age and nodal status, especially in hormone receptor-positive, HER2-negative disease.

LANCET ONCOLOGY (2021)

添加到收藏夹

Review Oncology

St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer

Christoph Thomssen et al.

Summary: Due to the COVID-19 pandemic, the 2021 St. Gallen/Vienna Consensus Conference on Early Breast Cancer Treatment Standards had to be held virtually, where organizers successfully managed to convene global contributors, leading to well-received scientific discussions with over 3,400 participants from 100+ countries. The virtual format introduced new elements such as audience-suggested Consensus questions and live audience interaction, doubling discussion time across different time zones.

BREAST CARE (2021)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer

Stephanie M. Wong et al.

ANNALS OF SURGICAL ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

J. A. Sparano et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy

Oriana A. Petruolo et al.

ANNALS OF SURGICAL ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection

Abigail S. Caudle et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study

Jean-Francois Boileau et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

添加到收藏夹

Article Surgery

Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer Findings From the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial

Judy C. Boughey et al.

ANNALS OF SURGERY (2014)

添加到收藏夹

Article Medicine, General & Internal

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Patricia Cortazar et al.

LANCET (2014)

添加到收藏夹

Article Medicine, General & Internal

Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer The ACOSOG Z1071 (Alliance) Clinical Trial

Judy C. Boughey et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)

添加到收藏夹

Article Oncology

Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study

Thorsten Kuehn et al.

LANCET ONCOLOGY (2013)

添加到收藏夹

Article Medicine, General & Internal

Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials

O Abe et al.

LANCET (2005)

添加到收藏夹

Article Medicine, General & Internal

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials

O Abe et al.

LANCET (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.